At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNM Immunome Inc.
Market Closed 09-27 16:00:00 EDT
14.38
+0.04
+0.28%
盘后15.08
+0.70+4.85%
19:46 EDT
High15.20
Low14.37
Vol2.35M
Open14.53
D1 Closing14.34
Amplitude5.79%
Mkt Cap863.58M
Tradable Cap618.58M
Total Shares60.05M
T/O34.76M
T/O Rate5.45%
Tradable Shares43.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
TD Cowen Sticks to Its Buy Rating for Immunome (IMNM)
Immunome to Present Updated Results for Ringside Phase 2 Trial of Al102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (Esmo) Congress 2024
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.